InflaRx (NASDAQ:IFRX) Given New $14.00 Price Target at Guggenheim

InflaRx (NASDAQ:IFRX) had its target price decreased by investment analysts at Guggenheim from $22.00 to $14.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Several other equities analysts also recently issued reports on IFRX. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price objective (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a report on Monday, December 29th. Raymond James Financial reissued an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of InflaRx in a research note on Tuesday, December 30th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, InflaRx currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.17.

InflaRx Stock Up 3.4%

Shares of IFRX stock opened at $0.91 on Friday. InflaRx has a 12-month low of $0.71 and a 12-month high of $1.94. The company has a market capitalization of $61.06 million, a P/E ratio of -1.34 and a beta of 1.48. The firm has a 50-day moving average price of $0.93 and a 200 day moving average price of $1.15.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.17) earnings per share for the quarter, hitting the consensus estimate of ($0.17). The firm had revenue of ($0.04) million for the quarter, compared to the consensus estimate of $0.03 million. As a group, research analysts expect that InflaRx will post -1.04 earnings per share for the current year.

Hedge Funds Weigh In On InflaRx

Several large investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC increased its position in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares during the period. Boothbay Fund Management LLC grew its position in shares of InflaRx by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock worth $235,000 after buying an additional 17,056 shares during the period. Concurrent Investment Advisors LLC raised its stake in shares of InflaRx by 56.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after buying an additional 19,200 shares during the last quarter. Eversept Partners LP raised its stake in shares of InflaRx by 1.5% during the fourth quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after buying an additional 26,677 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in InflaRx by 29.1% in the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after buying an additional 42,489 shares during the period. Institutional investors and hedge funds own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.